Cinagen-XG
Generic Name
Olopatadine Hydrochloride and Ketorolac Tromethamine Ophthalmic Solution
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| cinagen xg 05 04 eye drop | ৳ 150.00 | N/A |
Description
Overview of the medicine
Cinagen-XG 05-04 Eye Drop is an ophthalmic solution containing Olopatadine Hydrochloride and Ketorolac Tromethamine, indicated for the treatment of allergic conjunctivitis and associated ocular inflammation.
Uses & Indications
Dosage
Adults
Instill 1 drop in the affected eye(s) twice daily (approximately 8 hours apart), or as directed by a physician.
Elderly
No specific dosage adjustment is required for elderly patients.
Renal_impairment
No dosage adjustment is required for patients with renal impairment for ophthalmic use.
How to Take
For ophthalmic use only. Tilt head back, pull down the lower eyelid to form a pouch, and instill the drop into the conjunctival sac. Avoid touching the dropper tip to the eye or any other surface.
Mechanism of Action
Olopatadine acts as a selective H1-receptor antagonist and mast cell stabilizer, reducing histamine-mediated allergic reactions. Ketorolac inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing inflammation and pain.
Pharmacokinetics
Onset
Olopatadine: within minutes for itching relief. Ketorolac: within hours for anti-inflammatory effect.
Excretion
Primarily renal excretion for both active ingredients (systemic).
Half life
Olopatadine plasma half-life is approximately 3 hours (systemic). Ketorolac plasma half-life is approximately 4-6 hours (systemic, negligible for ophthalmic use).
Absorption
Minimal systemic absorption following ocular administration. Acts locally in the eye.
Metabolism
Olopatadine: primarily hepatic, minimal metabolism. Ketorolac: extensively metabolized in the liver, primarily via hydroxylation and conjugation.
Side Effects
Contraindications
- Hypersensitivity to Olopatadine, Ketorolac, or any excipients in the formulation.
- Patients with known allergic reactions to other NSAIDs.
Drug Interactions
Systemic NSAIDs
Although systemic absorption is minimal, caution is advised when co-administering with systemic NSAIDs due to potential additive effects on platelet function or gastrointestinal irritation (theoretical).
Other Ophthalmic Preparations
If using other eye drops, instill them at least 5 minutes apart.
Storage
Store at room temperature (below 30°C). Protect from light and moisture. Do not freeze.
Overdose
Ophthalmic overdose is unlikely to cause systemic toxicity. If swallowed, supportive and symptomatic treatment should be initiated.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing mother. Consult a physician.
Side Effects
Contraindications
- Hypersensitivity to Olopatadine, Ketorolac, or any excipients in the formulation.
- Patients with known allergic reactions to other NSAIDs.
Drug Interactions
Systemic NSAIDs
Although systemic absorption is minimal, caution is advised when co-administering with systemic NSAIDs due to potential additive effects on platelet function or gastrointestinal irritation (theoretical).
Other Ophthalmic Preparations
If using other eye drops, instill them at least 5 minutes apart.
Storage
Store at room temperature (below 30°C). Protect from light and moisture. Do not freeze.
Overdose
Ophthalmic overdose is unlikely to cause systemic toxicity. If swallowed, supportive and symptomatic treatment should be initiated.
Pregnancy & Lactation
Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing mother. Consult a physician.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months (unopened). Discard 28 days after opening.
Availability
Pharmacies, Hospitals
Approval Status
DGDA Approved
Patent Status
Generic available
Clinical Trials
Clinical trials have demonstrated the efficacy and safety of this combination ophthalmic solution for its approved indications.
Lab Monitoring
- Routine laboratory monitoring is not typically required for ophthalmic use of this medication.
Doctor Notes
- Advise patients to report any severe eye pain, vision changes, or persistent irritation immediately.
- Educate patients on proper contact lens management when using eye drops.
- Consider patient's history of NSAID sensitivity before prescribing.
Patient Guidelines
- Remove contact lenses before instilling the eye drop and wait at least 15 minutes before reinserting them.
- Do not touch the dropper tip to any surface to avoid contamination.
- Wait at least 5 minutes before administering other ophthalmic medications.
Missed Dose Advice
If a dose is missed, apply it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.
Driving Precautions
This medication may cause temporary blurred vision or other visual disturbances. Exercise caution when driving or operating machinery until your vision is clear.
Lifestyle Advice
- Avoid rubbing your eyes, as this can worsen irritation or infection.
- If you experience light sensitivity, wearing sunglasses may provide comfort.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.